A detailed history of Engineers Gate Manager LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 51,757 shares of NTLA stock, worth $787,223. This represents 0.02% of its overall portfolio holdings.

Number of Shares
51,757
Previous 61,528 15.88%
Holding current value
$787,223
Previous $1.38 Million 22.75%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $192,684 - $267,334
-9,771 Reduced 15.88%
51,757 $1.06 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $1.23 Million - $1.67 Million
61,528 New
61,528 $1.38 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $510,441 - $739,026
16,143 Added 224.02%
23,349 $738,000
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $1.31 Million - $1.74 Million
-37,881 Reduced 84.02%
7,206 $293,000
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $217,115 - $292,226
6,520 Added 16.91%
45,087 $1.68 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $335,719 - $633,733
10,109 Added 35.52%
38,567 $1.35 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $1.53 Million - $2.04 Million
28,458 New
28,458 $1.59 Million
Q1 2021

May 17, 2021

SELL
$46.59 - $83.68 $705,838 - $1.27 Million
-15,150 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$18.83 - $63.53 $570,323 - $1.92 Million
-30,288 Reduced 66.66%
15,150 $824,000
Q3 2020

Nov 16, 2020

BUY
$17.47 - $24.93 $793,801 - $1.13 Million
45,438 New
45,438 $903,000
Q2 2020

Aug 17, 2020

SELL
$11.14 - $22.87 $273,364 - $561,206
-24,539 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$9.44 - $15.58 $231,648 - $382,317
24,539 New
24,539 $300,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.16B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.